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Acute lower respiratory infection (ALRI) due to RSV is a common cause of global infant mortality, with most cases occurring in
developing countries. Using data aggregated from priority countries as designated by the United States Agency for International
Development’s (USAID) Maternal Child Health and Nutrition (MCHN) program, we created an adjustable algorithmic tool for
visualizing the effectiveness of candidate maternal RSV vaccination on infant mortality. Country-specific estimates for disease
burden and case fatality rates were computed based on established data. Country-specific RSV-ALRI incidence rates for infants
0-5 months were scaled based on the reported incidence rates for children 0-59 months. Using in-hospital mortality rates and
predetermined “inflation factor,” we estimated the mortality of infants aged 0-5 months. Given implementation of a candidate
maternal vaccination program, estimated reduction in infant RSV-ALRI incidence and mortality rates were calculated. User
input is used to determine the coverage of the program and the efficacy of the vaccine. Using the generated algorithm, the
overall reduction in infant mortality varied considerably depending on vaccine efficacy and distribution. Given a potential
efficacy of 70% and a maternal distribution rate of 50% in every USAID MCHN priority country, annual RSV-ALRI-related
infant mortality is estimated to be reduced by 14,862 cases. The absolute country-specific reduction is dependent on the number
of live births; countries with the highest birth rates had the greatest impact on annual mortality reduction. The adjustable
algorithm provides a standardized analytical tool in the evaluation of candidate maternal RSV vaccines. Ultimately, it can be
used to guide public health initiatives, research funding, and policy implementation concerning the effectiveness of potential
maternal RSV vaccination on reducing infant mortality.
1. Introduction
Globally, acute lower respiratory infection (ALRI) is a major
contributor to infant morbidity and mortality. Respiratory
syncytial virus (RSV) is one of the most commonly identified
etiologic viral pathogens leading to ALRI [1–3]. According to
Shi et al., an estimated 59,600 children less than 5 years old
died in-hospital in 2015 from RSV-related ALRI. Infants less
than six months of age made up 46% of the affected popula-
tion. An overwhelming majority of cases of RSV-induced
ALRI occur in developing countries [1].
The prevention and treatment of RSV poses a great finan-
cial burden; an estimated 50-70% of infants become infected
with RSV during their first winter season [4]. Current treat-
ment of RSV-related ALRI in children remains focused in
supportive care, including respiratory support and hydration
[3, 5, 6]. A humanized monoclonal antibody, Palivizumab, is
the only available prophylactic treatment [7]. Due to the high
cost, this medication is reserved for high-risk patients [7].
Additionally, natural infection has not provided long-term
immunity or adequate amounts of neutralizing antibodies
[8]. Reinfection rates can be as high as 83% depending on
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Figure 1: USAID’s MCHN map. This map depicts USAID’s MCHN priority countries that were investigated in creation of the algorithmic
tool to assess effectiveness of candidate maternal RSV vaccination on reducing infant incidence and mortality in developing countries. Data
for South Sudan were not available.
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Figure 2: Flowchart of calculation of country-specific infant (0-5 months) RSV incidence.
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the season [9]. The high cost of care and lack of unanimously
efficacious and widely available pharmaceutical interventions
paired with and high incidence, reinfection, and death rates
in infants <6 months old make potential maternal vaccina-
tion an attractive option in reducing disease burden [6].
An analysis of cost-effectiveness published by Cromer
et al. compares the various strategies for preventing and
treating RSV-related illness. The most economic strategies
were single dose protection that could be given to specifically
protect infants born just prior the start of RSV season [7].
Maternal vaccination during pregnancy, notably in the third
trimester, can provide transient passive immunity to infants
via immunoglobulin transfer through the placenta [10]. It is
estimated that the antibodies can be protective for up to 6
months before decaying. Because a large portion of antibody
transfer occurs in the third trimester, preterm infants are at a
greater risk for severe infections that could be avoided with
maternal vaccination [11].
Some ambiguity remains in identifying the immune
response and target most effective in providing immunity
to RSV [6]. The RSV F glycoprotein, a class I fusion protein,
and the RSV F prefusion form have been major targets of
interest for candidate vaccines. These proteins mediate viral
entry and are essential to the pathogenicity of the virus
[12]. A number of maternally indicated RSV F protein vac-
cines have been investigated both preclinically and through
clinical trials. Novavax, a RSV F vaccine, has completed clin-
ical trial and has been published [13]. Both Pfizer and Glax-
oSmithKline have RSV prefusion F vaccines in phase 3 of
clinical trial [14, 15].
Though the need for an approved and effective RSV vac-
cination is currently unmet, we created an adjustable algo-
rithmic tool for visualizing the effectiveness of candidate
maternal RSV vaccination on reducing disease incidence
and infant mortality. We used data specific to priority coun-
tries as designated by the United States Agency for Interna-
tional Development (USAID) Maternal Child Health and
Nutrition (MCHN) program as depicted in Figure 1 [16].
This tool can be used to quantify the expected benefit of vac-
cination implementation.
2. Methods
Based on data from Shi et al. [1], USAID MCHN country-
specific estimates for RSV disease burden and case fatality
rates among infants age 0-5 months given implementation
of a candidate vaccination program were computed. The
population of interest is infants <6 months of age (0-5
months) because of the anticipated benefit of transient
maternal antibody transfer. Data were collected, calculated,
Country-specific RSV-ALRI
hospitalization rate and in
hospital mortality rate by age
band
(0–1 month, 1–2 months,
3–5 months)
Country-specific live births –
(Country-specific live births ×
Country-specific mortality rate
of previous age band)
= absolute number of infants




= total in-hospital mortalities
by age band
In-hospital mortality
0–1 months + 1–2 months + 2–5
months






= absolute RSV-ALRI infant
mortalities 0-5 months (AM)
⁎User determined efficacy (E) and
distribution (D)
AM×(1 – E×D)
Estimated Country-specific RSV-ALRI 0-5 month
mortality given maternal RSV vaccination program
(IMV)
Figure 3: Flowchart of calculation of country-specific infant (0-5 months) RSV mortality.
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and reported by both country and region-specific estimates.
Efficacy of the vaccine and distribution to pregnant women
are determined by user input.
Absolute value of RSV incidence by country was calcu-
lated for infants age 0-5 months using the following scale.
Regional RSV incidence rates were obtained from the litera-
ture for infants age 0-5 months (RI:0-5) and children age 0-
59 months (RI:0-59). Using these rates as a scale along with
the reported country-specific RSV incidence rates for chil-
dren 0-59 months (CI:0-59), we estimated the country-
specific RSV incidence rates for infants age 0-5 months
(CI:0-5) by equating the regional and country-specific ratios
using Equation (1).
RI : 0 − 5
RI : 0 − 59 =
CI : 0 − 5
CI : 0 − 59 : ð1Þ
Then, the country-specific incidence rate for infants 0-5
months old was multiplied by the number of live births in
each country to obtain the absolute incidence of RSV for each
country [10]. Using this value, and user determined values
for efficacy and distribution of a candidate vaccine, the inci-
dence of RSV given implementation of a candidate vaccina-
tion program is estimated using Equation (2). The process
of the calculation of infant RSV incidence given candidate
maternal RSV vaccination is displayed in Figure 2.
AI × 1 − E ×Dð Þ = DBV, ð2Þ
AI:Absolute incidence
E:Efficacy
D:Distribution to pregnant women
DBV:Estimated RSV disease burden postmaternal vac-
cine implementation.
Infant RSV incidence was also calculated using region-
wide incidence rate estimates. The regional RSV incidence
rate for infants 0-5 months was multiplied by country-
specific live birth rates yielding the absolute incidence of
RSV in each country based on region wide estimates. Using
this value, and user determined values for efficacy and distri-
bution of a candidate vaccine, we estimate the reduction in
incidence of RSV given implementation of a vaccination
program.
Next, infant RSV mortality rate given implementation of
a candidate maternal vaccination program was calculated.
RSV hospitalization rates were reported by age bands: 0-1
month, 1-2 months, and 2-5 months. Using the country-
specific number of live births and mortality rate, we first cal-
culated the absolute number of infants age 0-1 month-old, 1-
2 months old, and 2-5 months old [17]. Neonatal and infant
mortality rates were obtained from http://data.unicef.org,
using 2016 midyear estimates throughout [18, 19]. The
mortality rates for infants 2-5 months old were calculated
assuming that the mortality rate in each country was con-
stant across months 2-12. The purpose of this calculation
was to adjust the absolute number of infants in older age
brackets and to account for infant mortalities that are
unrelated to RSV.
We then multiplied the absolute number of infants in
each age group by reported age-specific hospitalization rates
and in-hospital mortality rates. Additionally, we multiplied
by a predetermined inflation factor to account for infant
RSV mortalities that occurred outside of the hospital setting
[1]. The summation of the age bands results in the absolute
RSV mortality for infants age 0-5 months. Using this value,
and user determined values for efficacy and distribution of
a candidate vaccine, we estimate the RSV infant mortality
given implementation of a vaccination program using Equa-
tion (3). The process of the calculation of infant RSV mortal-
ity given candidate maternal RSV vaccination is displayed in
Figure 3.
AM× 1 − E ×Dð Þ = IMV, ð3Þ
AM:Absolute RSV-ALRI infant mortality
E:Efficacy
D:Distribution to pregnant women
IMV:Estimated RSV-ALRI infant mortality postmaternal
vaccine implementation.
Infant RSV-ALRI mortality rate given implementation of
a candidate maternal vaccination program was also calcu-
lated using region-wide estimates for hospitalization rates
and in-hospital mortality rates.
Figure 4: Control panel for interactive tool. The control panel of the
web-based interactive tool that is used to assess the efficacy of
candidate maternal RSV vaccination implementation at reducing
infant disease incidence and mortality in developing countries is
depicted. The user selects a country from the USAID MCHN
priority countries list, the percentage of expectant mothers to
receive the vaccine, and maternal vaccine effectiveness at
preventing RSV in infants age 0-5 months. The user then chooses
if they want incidence and mortality rates to be calculated using
the low or high end of published estimates. Finally, the user selects
if they prefer data to be displayed by country-specific or region-
wise estimates.
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We assumed that vaccination success was binary, in that
the vaccine only prevents RSV and does not reduce virulence
or severity of disease. Programing was carried out in R, and
the interactive visualizations were produced with the R Pack-
age Shiny.
3. Results
We have developed a web-based interactive tool that can be
used to assess the efficacy of candidate maternal RSV vacci-
nation implementation at reducing infant disease incidence
and mortality in developing countries. Using the control
panel (Figure 4), the user selects a country of choice from
the list of USAID’s MCHN priority countries, the percentage
of pregnant mothers expected to receive the vaccine, and
maternal vaccine effectiveness at preventing RSV in infants
age 0-5 months. Additionally, the user can decide their con-
fidence in the calculations by using the web controls to adjust
toward the low or high end of estimated values. Data can also
be displayed using country-specific or region wide estimates.
The resultant values are directly compared to the incidence
and mortality estimates with no vaccine intervention.
An example of the visualization of the interactive tool is
shown in Figure 5. If the user is interested in implementing
a candidate maternal RSV vaccine in Pakistan, they would
first select this country from the dropdown menu. They
could then set a vaccine distribution and efficacy. If the distri-
bution to pregnant mothers was estimated at 50% and the
efficacy was estimated at 70%, over 195,000 cases of RSV
and over 1,100 RSV-ALRI mortalities could have been
avoided in Pakistan alone. The algorithm also reports that
if this program was implemented in every USAID MCHN
priority country, over 2 million cases of RSV and nearly
15,000 infant mortalities could be avoided annually.
The absolute reduction in incidence and infant mortality
are most dramatic in countries with higher birth rates such as
India, Nigeria, and Pakistan.
This tool is unique in that the user can determine the var-
iables to best fit their purpose. It can give perspective and
account for a highly effective vaccine that has decreased dis-
tribution due to cost or need for refrigeration or a vaccine
with lower efficacy but a greater ability to be distributed.
4. Discussion
The treatment and prevention of RSV-related ALRI is multi-
faceted; maternal vaccination provides only one approach for







































































In Pakistan, the vaccination program would reduce the number of RSV-related cases of ALRI among children age 0–5 months
from 558207 to 362835, avoiding 195372 illnesses and 1176 deaths annually.












Figure 5: Algorithm visualization. An example of the visualization produced from the online tool. If the user is interested in implementing a
candidate maternal RSV vaccine in Pakistan, they would select this country from the dropdownmenu. If the distribution to pregnant mothers
was estimated at 50% and the efficacy was estimated at 70%, over 195,000 cases of RSV and over 1,100 RSV-ALRI mortalities could have been
avoided in Pakistan alone. The algorithm also reports that if this program were implemented in every USAIDMCHN priority country, over 2
million cases of RSV and nearly 15,000 infant mortalities could be avoided annually.
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gone into developing childhood vaccines and pharmaceutical
treatments. Conducting experimental RSV treatments on
children and infants has proved difficult due to the sensitivity
of the population and disease acuteness [10]. We chose to
investigate the effects of maternal vaccination due to its
well-established record of being an effective system for infant
disease and mortality prevention [20]. Tetanus, Pertussis,
and Influenza are examples of routine prenatal vaccines that
could model the efficacy of maternal RSV vaccine implemen-
tation [21]. The distribution of existing vaccines can provide
predictive power in determining the distribution of candidate
vaccines. Furthermore, similar algorithms could be generated
to visualize the effects of these existing vaccines on reducing
disease burden in developing countries.
Anticipation of maternal RSV vaccine availability has led
to a number of mathematical tools to estimate effectiveness of
vaccine implementation. A model created by Hogan et al.,
based on data from Western Australia, reports that an RSV
vaccine with a distribution of 50% and an efficacy of 80%
could reduce hospital admissions by 26% for infants <3
months of age and 40% for infants age 3-5 months [20]. Data
from Kenya estimated that maternal vaccination could
reduce infant RSV incidence rates by up to 31.5% [22]. A pre-
dictive model created by Scheltema et al., using data from the
United Kingdom and the Netherlands, estimated reductions
in NICU admissions by 62% and RSV-related in-hospital
infant deaths by up to 48%, given administration of variably
effective maternal RSV vaccination at 30 weeks gestation
[23]. These studies share the common expectation with our
model that efficacy of passive immunity decreases dramati-
cally as infant age increases and transient maternal antibod-
ies decay.
Rainisch et al. also utilized the Shi et al. [1] data set to
generate a model to assess RSV infant immunity strategies
in the United States [24]. Three different potential immuni-
zation strategies were compared by effectiveness of reducing
outcomes: monthly palivizumab therapy for high-risk
infants, infant indicated one-time antibody therapy for all
infants, and maternal vaccination for all plus palivizumab
for high-risk infants. Based on their calculations, an infant
indicated antibody treatment would prevent the largest num-
ber of out-patient visits, emergency department visits, and
hospitalizations in the United States [24]. However, the study
did not include a strategy solely dedicated to maternal vacci-
nation, as is the focus of our model. Additionally, the impact
of all immunization strategies on infant mortality was lim-
ited. Our model found greater impacts on mortality reduc-
tion with maternal vaccination likely due to the higher
incidence and mortality rates in developing countries.
Other infectious diseases that cause significant infant
mortality, such as Group B Strep, could be assessed in a sim-
ilar manner. Group B Strep (GBS) is detected in the vaginal
flora of 10-40% of reproductive age women [25]. Fetal and
infant infection with GBS can have severe outcomes includ-
ing preterm birth, neurological consequences, or death.
While most developed countries test for GBS intrapartum
and provide prophylactic intrapartum antibiotic treatment,
this practice is not widely used in developing countries
[25]. An estimated 90,000 infants who become infected with
GBS die annually, and another 57,000 stillbirths can be asso-
ciated with ascending GBS infection [17]. As with RSV, the
burden of infant mortality and stillbirth is higher in develop-
ing countries [17]. The World Health Organization has rec-
ognized the development of a maternal GBS vaccine as a
priority [26]. GlaxoSmithKline’s GBS trivalent vaccine has
shown favorable results with effective transplacental anti-
body transfer to infants for up to 3 months of age [15, 27].
Using GBS infection data from developing countries, our
RSV algorithm could be used as a model for an adjustable
tool in the assessment of candidate maternal GBS vaccines.
A major limitation of this project was the manipulation
of data to fit the target population of infants age 0-5 months
in USAID MCHN countries. Due to the subjectivity of the
calculations and mathematical assumptions made, there is
possibility of error in our estimates. For this reason, we have
given the user opportunities to adjust the algorithm as neces-
sary, including adjusting calculations to fit low or high ends
of published estimates of disease incidence. In the future, if
new data become available, we can make direct comparisons
to our model and adjust accordingly to provide the most
accurate and up-to-date estimates.
5. Conclusion
The adjustable algorithm provides a standardized analytical
tool in assessing the effectiveness of candidate maternal
RSV vaccination on reducing infant disease and mortality
in developing countries. As vaccines continue through clini-
cal trials and become widely available, this algorithm can
provide foresight into vaccine application. Ultimately, it can
be used to guide public health initiatives, research funding,
and policy implementation concerning the impact of RSV
on developing countries.
Data Availability
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at https://chrisleary.shinyapps.io/RSVVaccination/.
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